Treating central precocious puberty since 19931

GnRH agonists are standard of care for treatment of central precocious puberty (CPP).2,3

lupron depot ped - central precocious puberty treatment

Long-term efficacy and safety data with LUPRON DEPOT-PED 1 month5

18 years


Clinical experience with LUPRON DEPOT-PED5-7

22 years


Support and savings

23 years

CPP=Central precocious puberty
GnRHa=Gonadotropin-releasing hormone.

References: 1. LUPRON DEPOT-PED [package insert]. North Chicago, IL: AbbVie Inc. 2. Carel JC, Eugster EA, Rogel A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123(4):e752-762. 3. Nabhan ZM and Walvoord EC. Treatment of gonadotropin‐dependent precocious puberty. In: Pescovitz OH, Walvoord EC, eds. When Puberty Is Precocious. Totowa, NJ. Humana Press; 2007:chap 16. 4. Data on File, AbbVie Inc, Source: Internal AbbVie prescription claims database analysis (April 1993-May 2016), 2016. 5. Lee PA, Neely EK, Fuqua J, et al. Efficacy of leuprolide acetate 1-month depot for central precocious puberty (CPP): growth outcomes during a prospective, longitudinal study. Int J Pediatr Endocrinol. 2011;2011(1):7. doi: 10.1186/1687-9856-2011-7. Epub 2011 Jul 12. 6. Lee PA, Klein K, Mauras N, et al. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab. 2012;97(5):1572-1580. 7. Lee PA, Klein K, Nauras N, et al. 35-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty. J Clin Endocrinol Metab. 2014;99(9):153-3159.